ABSTRACT The aim of this retrospective study was to establish a simple self-assessed scale for individual risk of cirrhosis in patients with chronic hepatitis B. A total of 1808 consecutive

patients were enrolled and analyzed. According to the results of multivariate logistic regression analysis, a simple nomogram was calculated for cirrhosis. The area under receiver operating

characteristic curves (AUROCs) were calculated to compare the diagnostic accuracy of nomogram with aspartate aminotransferase to platelet ratio index (APRI), fibrosis index based on the four

factors (FIB-4), and S index. The AUROCs of nomogram for cirrhosis were 0.807 (adjusted AUROC 0.876) in model group and 0.794 (adjusted AUROC0.866) in validation group. DeLong’s test and

In conclusion, as a self-assessed style, simple, non-invasive, economical, convenient, and repeatable scale, nomogram is suitable to serve as a massive health screening tool for cirrhosis in

CHB patients and further external validation is needed. SIMILAR CONTENT BEING VIEWED BY OTHERS A NOMOGRAM BASED ON PSOAS MUSCLE INDEX PREDICTING LONG-TERM CIRRHOSIS INCIDENCE IN

NON-CIRRHOTIC PATIENTS WITH HBV-RELATED ACUTE‑ON‑CHRONIC LIVER FAILURE Article Open access 02 December 2023 NOMOGRAMS FOR PREDICTING SHORT-TERM MORTALITY IN ACUTE-ON-CHRONIC LIVER DISEASE

CAUSED BY THE COMBINATION OF HEPATITIS B VIRUS AND ALCOHOL Article Open access 19 October 2024 A NON-INVASIVE DIAGNOSTIC NOMOGRAM FOR CHB-RELATED EARLY CIRRHOSIS: A PROSPECTIVE STUDY Article

Open access 03 July 2024 INTRODUCTION As a public health problem, hepatitis B virus (HBV) affected 350 million people in the world. The corresponding 5-year cumulative incidences of

cirrhosis were 8% and 17% in hepatitis B e antigen (HBeAg) positive patients in East Asian countries and European countries, whereas it were 13% and 38% in HBeAg negative patients,

respectively1. For patient with cirrhosis, the 5-year cumulative incidences of hepatocellular carcinoma (HCC) were 17% in East Asia and 10% in the Western Europe and the United States1. For

patients with compensated cirrhosis, the 5-year cumulative incidence of liver decompensation was 15% in European and Asian studies2,3,4. The 5-year liver related death incidences in patients

with compensated cirrhosis were 15% in Europe and 14% in East Asia, whereas it was 70% to 85% for patients with uncompensated cirrhosis4,5,6. There were over 200,000 and 300,000 chronic HBV

carriers died each year from cirrhosis and HCC, respectively7,8. Therefore, the early detection of cirrhosis is of significance for prevention of HCC and cirrhosis. Liver biopsy is the best

available standard in assessing cirrhosis but is limited by its invasiveness and sampling error9,10. Transient elastography (TE) has a better diagnostic value in detecting hepatic fibrosis.

However, it is difficult to obtain measurement data in case of obesity, ascites and limited operator experience11. It has been found that acute hepatitis, extrahepatic cholestasis and

congestion would result in elevated false positive and reduce the diagnostic accuracy12,13. In addition, TE is not readily available in most primary hospitals in developing countries. From

the perspective of clinical practice and cost-effectiveness, an ideal screening tool for cirrhosis should be a simple, non-invasive, economical, convenient and repeatable method.

Furthermore, personalized risk assessment of cirrhosis represents a challenge for management of patient with chronic hepatitis B. Nomogram which derived from hazard functions has been

applied to various diseases as a straightforward predictive tool14,15. The nomogram is convenient for clinicians and patients to assess the probability of disease without complex formula. In

addition, nomogram can provide straightforward individual risk assessment, which is readily comprehensible for patients without medical knowledge. Therefore, nomogram improves the clinical

significance from group-level to individual-level and is favorable for clinicians and patients. The aim of this study was to build and validate a simple nomogram for assessment of cirrhosis

in patients with chronic hepatitis B (CHB). PATIENTS AND METHODS PATIENTS This retrospective study included eligible patients diagnosed as chronic hepatitis B and had undergone liver biopsy

in department of infectious diseases of Shunde Hospital of Southern Medical University, between January 2008 and November 2014. The Patients were enrolled based on the following criteria:

chronic hepatitis B was defined as hepatitis B surface antigen (HBsAg) positivity for more than 6 months. The exclusion criteria were as follows: liver cancer; co-infection with hepatitis C

virus, hepatitis D virus or human immunodeficiency virus; autoimmune liver diseases such as autoimmune hepatitis, primary biliary cirrhosis, and primary sclerosing cholangitis; hereditary

and metabolic liver diseases such as Wilson’s disease, hemochromatosis, and α−1-antitrypsin deficiency. Therefore, there were 344 patients excluded from the current study according to above

criteria. There were no significant differences in terms of demographic and clinical parameters between patients included and excluded (data not shown). All data collections and clinical

investigations were performed according to the principles of Declaration of Helsinki. The study was approved by the ethics committee of Shunde Hospital of Southern Medical University. We

performed this study according to the STARD recommendations for the optimal quality in reporting diagnostic accuracy. LIVER BIOPSY Liver biopsies were performed by two experienced physicians

using a 16-gauge needle (16 G biopsy Menghini’s needle, ShangHai). Only the liver tissues with a length more than 1.5 cm were recruited in the present study. The specimens were fixed,

paraffin-embedded and stained with haematoxylin and eosin (HE). Histological grading of necro-inflammation (G0–G4) and staging of the liver fibrosis (S0–S4) were carried out according to

Scheuer classification16 by one experienced pathologist blinded to the clinical data. In the study, cirrhosis was defined as fibrosis stage = S4. SERUM MARKERS AND NONINVASIVE MODELS All

patients systematically underwent complete biochemical workups, ultrasonography and liver biopsy within 2 days. Blood samples of the subjects were obtained before liver biopsy. Biochemical

tests were performed in laboratory of Shunde Hospital of Southern Medical University for alanine aminotransferase (ALT,U/L), aspartate aminotransferase (AST,U/L), γ-glutamyl transferase

(GGT, U/L), total bilirubin (TBIL, mmol/L), white blood cell (WBC, 10^9/L), hemoglobin (HGB, g/L), platelet (PLT, 10^9/L), α-fetoprotein (AFP, ng/ml), hyaluronic acid (HA, μg/L), fasting

plasma glucose (FPG, mmol/L), total cholesterol (TC, mmol/L), triglycerides (TG, mmol/L), high-density lipoprotein cholesterol (HDL, mmol/L); low-density lipoprotein cholesterol (LDL,

mmol/L). The serum HBV-DNA level was detected with a Real-Time polymerase chain reaction (PCR) System (ABI7700; Applied Shenzhen city Daeran Biological Engineering Co Ltd, Shenzhen,

Guangdong, CHN). HBsAg was measured with CLIA systems (Abbott ARCHITECT i2000 SR system, Abbott Laboratories, Abbott Park, IL, USA). The formulas of aspartate aminotransferase to platelet

ratio index (APRI), fibrosis index based on the four factors (FIB-4), and S index were calculated as described in the original articles17,18,19. APRI: (AST/[ULN]/PLT [109/L])*100; FIB-4:

(age [year]*AST [U/L])/{ (PLT [109/L])* (ALT [U/L])1/2}; S index: 1000*GGT/ (PLT*ALB2). STANDARDISATION OF AUROC ACCORDING TO THE PREVALENCE OF FIBROSIS STAGES It has been found that the

prevalence of different liver fibrosis stages may be a major factor of variability in assessing the diagnostic accuracy of noninvasive model. Therefore, AUROC should be adjusted according to

the prevalence of fibrosis stages using the difference between advanced and non-advanced fibrosis (DANA) method20. DANA was calculated according to the following formula: DANA = 

[(prevalence F4*4)/ (prevalence F4)] – [prevalence F1 + prevalence F2*2 + prevalence F3*3/ (prevalence F0 + prevalence F1 + prevalence F2 + prevalence F3)]. The adjusted AUROC (AdjAUROC) was

calculated as follow: AdjAUROC = observed AUROC + 0.1056* (2.5 –DANA). DATA AVAILABILITY The datasets analyzed during the current study are available from the corresponding author on

reasonable request. STATISTICAL ANALYSIS Continuous data were expressed as mean ± standard deviation or median (minimum, maximum) depending on the normality of variables. Continuous

variables were compared by t-test or Mann-Whitney U test as appropriate. Categorical variables were compared by chi-squared test or Fisher’s exact test as appropriate. All variables that

significantly associated with fibrosis in univariate logistic regression analysis were included in forward stepwise multivariate logistic regression analysis to derive a nomogram for

cirrhosis. The area under receiver operating characteristic curves (AUROCs) were calculated to evaluate the diagnostic accuracy of nomogram in predicting cirrhosis and compared by DeLong’s

test21. Statistical analyses were performed using SPSS 19.0 (SPSS Inc., Chicago, IL). All statistical tests were two-sided. _P_ < 0.05 was considered statistically significant. RESULTS

THE CHARACTERISTICS OF SUBJECTS IN MODEL GROUP AND VALIDATION GROUP A total of 1808 patients were recruited into the present study with a mean age of 33.3 ± 9.6 years. Of all patients in the

current study, 1422 (78.7%) were male and 386 (21.3%) were female, 1143 (63.2%) were HBeAg positive and 665 (36.8%) were HBeAg negative. The fibrosis stages were 275 (15.2%) in S1, 656

(36.3%) in S2, 495 (27.4%) in S3 and 382 (21.1%) in S4. The inflammation grades were 113 (6.3%) in G1, 815 (45.1%) in G2, 643 (35.6%) in G3 and 237 (13.1%) in G4. The patients were randomly

divided into model group (n = 1080) and validation group (n = 728) using whole group random sampling method using SPSS 19.0. The baseline characteristics of patients in model group and

validation group were summarized in Table 1. NOMOGRAM FOR CIRRHOSIS All variables that significantly associated with cirrhosis in univariate logistic regression analysis were included in

multivariate logistic regression analysis (forward stepwise method) to derive a nomogram for cirrhosis (Table 2 and Fig. 1). At last, age, gender, α-fetoprotein (AFP), γ-glutamyl transferase

(GGT), hyaluronic acid (HA), Albumin and platelet (PLT) were included in the nomogram for cirrhosis. Nomogram = exp (1.117 + 0.03 × Age + 0.002 × GGT-0.053 × Albumin + 0.004 × HA-0.014 × 

PLT-0.002 × AFP + 0.484 × Gender)/{1 + exp (1.117 + 0.03 × Age + 0.002 × GGT-0.053 × Albumin + 0.004 × HA-0.014 × PLT-0.002 × AFP + 0.484 × Gender)}. DIAGNOSTIC ACCURACY OF NOMOGRAM FOR

CIRRHOSIS IN MODEL GROUP AND VALIDATION GROUP The receiver operating characteristic curve of nomogram was drawn to assess the diagnostic accuracy for cirrhosis (Fig. 2). The AUROCs of

nomogram, APRI, FIB-4 and S index for cirrhosis were 0.807 (AdjAUROC 0.876, 95%CI 0.773–0.841), 0.609 (AdjAUROC0.678, 95%CI 0.570–0.648), 0.710 (AdjAUROC0.779, 95%CI 0.673–0.748), and 0.730

(AdjAUROC0.799, 95%CI 0.695–0.766) in model group. In validation group, the AUROCs of nomogram, APRI,FIB-4 and S index were 0.794 (AdjAUROC0.866, 95%CI 0.755–0.834), 0.618 (AdjAUROC0.690,

95%CI 0.569–0.666), 0.727 (AdjAUROC0.796, 95%CI 0.682–0.771), and 0.726 (AdjAUROC0.794, 95%CI 0.680–0.773).Comparisons of AUROCs using DeLong’s test method demonstrated that nomogram was

significantly superior to APRI, FIB-4 and S index for both model group and validation group (all _P_ < 0.001). CALIBRATION CURVE OF NOMOGRAM FOR CIRRHOSIS The further calibration curve

was showed in Fig. 3. A calibration plot compares the model’s predicted probabilities and observed proportions. The diagonal line reflects the ideal situation (predicted probability = 

observed proportion). The calibration curve (Fig. 3) showed that the nomogram model appeared to be well-calibrated and there was a good agreement between the observed and predicted

probabilities of cirrhosis. THE BRIER SCORE OF FOUR DIAGNOSTIC INDEXES The Brier Score is the mean squared error of the probability forecasts over the verification sample, ranging from o to

1. Brier Score is a proper score function to measure the accuracy of probabilistic predictions and widely used for the verification of probability forecasts22,23. Therefore, the closer the

Brier Score is to 0, the better the calibration of the model. The Brier Score of nomogram, APRI, FIB-4 and S index for cirrhosis were 0.1217, 0.1627, 0.1523, and 0.1505 in model group. The

Brier Score of nomogram, APRI, FIB-4 and S index were 0.1334, 0.1649, 0.1560, and 0.1537 in validation group. The Brier Score of nomogram was significantly less than that of other three

indexes, indicating that nomogram had the highest predictive accuracy in four diagnostic indexes. CLINICAL UTILITY OF NOMOGRAM FOR CIRRHOSIS The optimal cut-off values for predicting

fibrosis were determined according to positive likelihood ratio (PLR) nearly 10.0 for high risk group and negative likelihood ratio (NLR) nearly 0.1 for low risk group24. For cirrhosis, the

high risk cut-off value of 0.52 showed a PLR 10.01, a specificity 96.9%, and a negative predictive value 84.0%. The low risk cut-off value of 0.07 showed a NLR 0.17, a sensitivity 95.6%, and

a positive predictive value 25.9%. The low positive predictive value (25.9%) for low risk cut-off value 0.07 was associated with low cirrhosis prevalence (21.1%) in the present study. The

patients with nomogram < 0.07 could be defined as low risk group with cirrhosis prevalence lower than 4.3% (17/397). The cirrhosis prevalence of patients in middle risk group (0.07 ≤

nomogram index ≤ 0.52) was 19.7% (246/1248). The patients with nomogram > 0.52 could be defined as high risk group with cirrhosis prevalence higher than 73.0% (119/163). DIAGNOSTIC

ACCURACY OF NOMOGRAM FOR PATIENTS WITHOUT ANTIVIRUS THERAPY We further explored the diagnostic accuracy of nomogram for patients without antivirus therapy (Fig. 4). For patients without

antivirus therapy in model group (n = 862), the AUROCs of nomogram, APRI, FIB-4 and S index for cirrhosis were 0.795 (95%CI 0.754–0.835), 0.603 (95%CI 0.558–0.647), 0.692 (95%CI

0.648–0.736), and 0.731 (95%CI 0.691–0.772). For patients without antivirus therapy in validation group (n = 576), the AUROCs of nomogram, APRI,FIB-4 and S index were 0.794 (95%CI

0.726–0.841), 0.628 (95%CI 0.570–0.685), 0.711 (95%CI 0.657–0.765), and 0.742 (95%CI 0.694–0.790). Comparisons of AUROCs using DeLong’s test method showed that nomogram was significantly

superior to APRI,FIB-4 and S index in patients without antivirus therapy. DISCUSSION A nomogram was derived for detection of cirrhosis in CHB patients. The AUROCs of nomogram for cirrhosis

were 0.807 (AdjAUROC 0.876) in model group and 0.794 (AdjAUROC0.866) in validation group. DeLong’s test and Brier Score demonstrated that nomogram was superior to other three indexes in both

model group and validation group for fibrosis. The patients with nomogram < 0.07 could be defined as low risk group with cirrhosis prevalence lower than 4.3% (17/397). The patients with

nomogram > 0.52 could be defined as high risk group with cirrhosis prevalence higher than 73.0% (119/163). Nomogram for cirrhosis involved PLT, age, AFP, GGT, HA, Albumin, and gender. All

these parameters had been found to be correlated with advanced fibrosis in previous studies. Platelet count was related with portal hypertension and advanced fibrosis25. Age had been

applied as a surrogate marker of disease duration and was correlated with advanced fibrosis25. AFP had been found to be correlated with hepatic impair and chronic fibrosis, thus AFP was

helpful to differential diagnosis of fibrosis stage26,27. Bile duct lesions caused by HBV infection could partially explain the elevated GGT and patients with elevated GGT often had

significantly higher fibrosis scores28,29. It had been found that serum HA level increased in chronic liver diseases and elevated serum HA was helpful to identify the progressive liver

damage30,31. The albumin was exclusively synthesized in live and albumin level fell along with the decline of hepatic synthetic function in patients with worsening liver fibrosis32. Albumin

level decreased in case of cirrhosis and had been utilized in Child-Pugh classification33. Gender had been utilized as a predictor for advanced fibrosis and cirrhosis in the predictive index

suggested by Wang _et al_.34. In the current study, these above parameters were confirmed as independent influence factors in multivariate logistic regression analysis. The diagnostic

accuracy of APRI, FIB-4 and S index in the current study was different to that in previous studies17,18,19. The differences of APRI, FIB-4 and S index in predicting cirrhosis might be

related to the following reasons. First, FIB-4 was constructed in patients with human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infection, whereas APRI was derived from

patients with HCV. HBV, HCV and HIV infection have different influences on clinical characteristics, progression of fibrosis and diagnostic markers. Second, the influence of different

prevalence of fibrosis stages in various studies should be taken into account for assessment of diagnostic accuracy of noninvasive indexes. Third, the inclusion of GGT, HA, albumin, age, and

gender might enhance the efficiency of nomogram in predicting cirrhosis compared with APRI, FIB-4 and S index. This nomogram is a good choice for massive screening in detecting cirrhosis as

an alternative to liver biopsy or examinations for the following reasons. First, this nomogram is easy to calculate by patients themselves without complex mathematical calculation.

Therefore, this nomogram provides a self-assessed scale of individual risk of cirrhosis to patients themselves. Second, this nomogram score is directly translated to a relative

individualized risk probability of cirrhosis, which is easy to understand for patients without medical knowledge. Third, all relevant parameters of this nomogram are readily available in

routine health examinations with no additional cost. Fourth, this nomogram is easily applicable for clinical practice because this nomogram does not need additional equipments, which is of

importance for most primary hospitals in developing countries. Fifth, the patients with nomogram <0.07 could be defined as low risk of cirrhosis with a correct rate of 95.7%. In summary,

as a self-assessed style, simple, non-invasive, economical, convenient and repeatable scale, it is worth considering utilizing this nomogram as a massive screening tool in selecting patients

for further imaging examinations or liver biopsy. The present study has several strengths as follows. Firstly, the present study finally included 1808 patients with CHB, providing a

convincing conclusion for diagnostic accuracy of cirrhosis. Secondly, the AUROCs in the current study were adjusted using DANA method to adjust the influence of different prevalence of

fibrosis stages, providing standard results for further comparisons in different studies. Thirdly, the Brier Score of four indexes further demonstrated that nomogram has the highest

predictive accuracy in four diagnostic indexes. The present study has three limitations which should be taken into account. First, this nomogram did not include some valuable variables such

asα2-macroglobulin and body mass index due to the present study was a retrospective study. Second, the present study was a single center study, which might reduce the representative of the

study population. Large scale and multi-center studies are needed to externally validate the diagnostic accuracy of nomogram. Third, HA is not a common parameter in conventional health

examination and may be a limitation for the application of nomogram in different study population. Therefore, this proposed nomogram requires further external studies and confirmations. In

conclusion, as a self-assessed style, simple, non-invasive, economical, convenient, and repeatable scale, nomogram is suitable to serve as a massive health screening tool for cirrhosis in

CHB patients and further external validation is needed. REFERENCES * Fattovich, G., Bortolotti, F. & Donato, F. Natural history of chronic hepatitis B: special emphasis on disease

progression and prognostic factors. _J Hepatol._ 48, 335–352 (2008). Article  PubMed  Google Scholar  * Xu, B. _et al_. Chronic hepatitis B: a long-term retrospective cohort study of disease

progression in Shanghai, China. _J Gastroenterol Hepatol._ 18, 1345–1352 (2003). Article  PubMed  Google Scholar  * Liaw, Y. F. _et al_. Cirrhosis Asian Lamivudine Multicentre Study Group.

Lamivudine for patients with chronic hepatitis B and advanced liver disease. _N Engl J Med._ 351, 1521–1531 (2004). Article  CAS  PubMed  Google Scholar  * Fattovich, G. _et al_. Effect of

hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. _Am J Gastroenterol_ 97, 2886–2895 (2002). Article  PubMed  Google Scholar

  * Fattovich, G. Natural history and prognosis of hepatitis B. _Semin Liver Dis._ 23, 47–68 (2003). Article  PubMed  Google Scholar  * Hui, A. Y. _et al_. Survival and prognostic indicators

in patients with hepatitis B virus-related cirrhosis after onset of hepatic decompensation. _J Clin Gastroenterol._ 34, 569–572 (2002). Article  PubMed  Google Scholar  * EASL International

Consensus Conference on Hepatitis B. Consensus statement. _J Hepatol_. 38, 533–540 (2003). * Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J. & Bell, B. P. The

contribution of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. _J Hepatol._ 45, 529–538 (2006). Article  PubMed  Google Scholar  *

Shackel, N. A. & McCaughan, G. W. Liver biopsy: is it still relevant. _Intern Med J._ 36, 689–691 (2006). Article  CAS  PubMed  Google Scholar  * Emanuele, E. Is biopsy always necessary?

Toward a clinico-laboratory approach for diagnosing nonalcoholic steatohepatitis in obesity. _Hepatology._ 48, 2086–2087 (2008). Article  PubMed  Google Scholar  * Castera, L. _et al_.

Pitfalls of liver stiffness measurement: a 5-year prospective study of 13,369 examinations. _Hepatology._ 51, 828–835 (2010). PubMed  Google Scholar  * Chen, Y. P., Peng, J. & Hou, J. L.

Non-invasive assessment of liver fibrosis in patients with chronic hepatitis B. _Hepatol Int._ 7(2), 356–368 (2013). Article  PubMed  Google Scholar  * Liang, X. E. _et al_. Dynamic

evaluation of liver stiffness measurement to improve diagnostic accuracy of liver cirrhosis in patients with chronic hepatitis B acute exacerbation. _J Viral Hepat._ 18(12), 884–891 (2011).

Article  PubMed  Google Scholar  * Zhang, Z. Q., Wang, G. S., Kang, K. F., Wu, G. B. & Wang, P. Nomogram for hepatic steatosis: A simple and economical diagnostic tool for massive

screening. _Dig Liver Dis._ 48(8), 914–920 (2016). Article  PubMed  Google Scholar  * Hsu, C. Y. _et al_. Surgical resection is better than transarterial chemoembolization for patients with

hepatocellular carcinoma beyond the Milan criteria: a prognostic nomogram study. _Ann Surg Oncol._ 23, 994–1002 (2016). Article  PubMed  Google Scholar  * European Association for the study

of the liver. EASL clinical practice guidelines: management of chronic hepatitis B. _J Hepatol_. 50, 227–242 (2009). * Wai, C. T. _et al_. A simple noninvasive index can predict both

significant fibrosis and cirrhosis in patients with chronic hepatitis C. _Hepatology._ 38, 518–526 (2003). Article  PubMed  Google Scholar  * Valet-pichard, A. _et al_. FIB-4:an inexpensive

and accurate marker of fibrosis in HCVinfection.comparison with liver biopsy and Fibrotest. _Hepatology._ 46(1), 32–36 (2007). Article  Google Scholar  * Zhou, K. _et al_. Simpler score of

routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. _J Gastroenterol Hepatol_ 25(9), 1569–1577 (2010). Article  PubMed  Google Scholar  * Poynard, T., _et

al_. Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages. _Clin Chem_. 53, 1615–1622 (2007). * DeLong, E. R.,

DeLong, D. M. & Clarke-Pearson, D. L. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. _Biometrics._ 44(3), 837–845

(1988). Article  CAS  PubMed  MATH  Google Scholar  * Brier, G.W. Verification of forecasts expressed in terms of probability. _Mon Weather Rev_.1-3 (1950). * Lin, B. _et al_. Entecavir

improves the outcome of acute-on- chronic liver failure due to the acute exacerbation of chronic Hepatitis B. _Hepatol Int._ 7(2), 460–467 (2013). Article  PubMed  Google Scholar  *

Jaeschke, R., Guyatt, G. & Sackett, D. L. Users’guides to the medical literature.III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence

-Based Medicine Working Group. _JAMA._ 271, 389–391 (1994). Article  CAS  PubMed  Google Scholar  * Sterling, R. K. _et al_. A comparison of the spectrum of chronic hepatitis C virus between

Caucasians and African Americans. _Clin Gastroenterol Hepatol_ 2, 469–473 (2004). Article  PubMed  Google Scholar  * Tian, L. _et al_. Serological AFP/Golgi protein 73 could be a new

diagnostic parameter of hepatic diseases. _Int J Cancer._ 129, 1923–1931 (2011). Article  CAS  PubMed  Google Scholar  * Xiao, L., _et al_. Parameters associated with significant liver

histological changes in patients with chronic hepatitis B. _ISRN Gastroenterol_. 913890 (2014). * Forns, X. _et al_. Identification of chronic hepatitis C patients without hepatic fibrosis

by a simple predictive model. _Hepatology._ 36, 986–992 (2002). Article  PubMed  Google Scholar  * Myers, R. P., Ratziu, V., Imbert-Bismut, F., Charlotte, F. & Poynard, T. Biochemical

markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. _Am J Gastroenterol._ 97, 2419–2425 (2002). Article  CAS  PubMed  Google Scholar  *

Rosenberg, W. M. _et al_. Serum markers detect the presence of liver fibrosis: a cohort study. _Gastroenterology._ 127, 1704–1713 (2004). Article  PubMed  Google Scholar  * Murawaki, Y.,

Ikuta, Y., Okamoto, K., Koda, M. & Kawasaki, H. Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic

hepatitis C. _J Gastroenterol_ 36, 399–406 (2001). Article  CAS  PubMed  Google Scholar  * Fahim, F. A., Esmat, A. Y., Hassan, G. K. & Abdel-Bary, A. Biochemical changes in patients with

combined chronic schistosomiasis and viral hepatitis C infections. _Dis Markers._ 16, 111–118 (2000). Article  CAS  PubMed  PubMed Central  Google Scholar  * Pugh, R. N., Murray-Lyon, I.

M., Dawson, J. L., Pietroni, M. C. & Williams, R. Transection of the oesophagus for bleeding oesophageal varices. _Br J Surg._ 60(8), 646–649 (1973). Article  CAS  PubMed  Google Scholar

  * Wang, Y. _et al_. Prediction of significant fibrosis and cirrhosis in hepatitis B e-antigen negative patients with chronic hepatitis B using routine parameters. _Hepatol Res._ 43(5),

441–451 (2013). Article  CAS  PubMed  Google Scholar  Download references ACKNOWLEDGEMENTS We sincerely appreciated the help from Professor Gongsui Wang in the current study. This study was

funded by Guangdong Provincial Health Department (Nos: A2013695 and A2016450). The authors that received the funding were Peng Wang (No: A2013695) and Zhiqiao Zhang (No: A2016450). The

funders had no role in study design, data collection and analysis, decision to publish, preparation, or writing of the manuscript. The URLs of Guangdong Provincial Health Department Was

http://www.gdwst.gov.cn/. AUTHOR INFORMATION Author notes * Zhiqiao Zhang and Jing Li contributed equally to this work. AUTHORS AND AFFILIATIONS * Department of Infectious Diseases, Shunde

Hospital of Southern Medical University, Shunde, Guangdong, China Zhiqiao Zhang, Jing Li, Peng Wang, Tingshan He, Yanling Ouyang & Yiyan Huang Authors * Zhiqiao Zhang View author

publications You can also search for this author inPubMed Google Scholar * Jing Li View author publications You can also search for this author inPubMed Google Scholar * Peng Wang View

author publications You can also search for this author inPubMed Google Scholar * Tingshan He View author publications You can also search for this author inPubMed Google Scholar * Yanling

Ouyang View author publications You can also search for this author inPubMed Google Scholar * Yiyan Huang View author publications You can also search for this author inPubMed Google Scholar

CONTRIBUTIONS Z.Z., J.L., and P.W. designed the study. Z.Z. and J.L. performed the research; T.H., Y.O., and Y.H. collected and analyzed the data; P.W. and Z.Z. wrote the paper; P.W. and

Z.Z. acted as the submission’s guarantor and takes responsibility for the integrity of the work as a whole, from inception to published article. All authors reviewed the manuscript.

CORRESPONDING AUTHOR Correspondence to Peng Wang. ETHICS DECLARATIONS COMPETING INTERESTS  The authors declare that they have no competing interests. ADDITIONAL INFORMATION PUBLISHER'S

NOTE: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. RIGHTS AND PERMISSIONS OPEN ACCESS This article is licensed under

a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate

credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article

are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and

your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this

license, visit http://creativecommons.org/licenses/by/4.0/. Reprints and permissions ABOUT THIS ARTICLE CITE THIS ARTICLE Zhang, Z., Li, J., Wang, P. _et al._ Nomogram for cirrhosis in

patients with chronic hepatitis B: A simple self-assessed scale for individual risk of cirrhosis. _Sci Rep_ 7, 17493 (2017). https://doi.org/10.1038/s41598-017-17685-4 Download citation *

Received: 22 June 2017 * Accepted: 29 November 2017 * Published: 13 December 2017 * DOI: https://doi.org/10.1038/s41598-017-17685-4 SHARE THIS ARTICLE Anyone you share the following link

with will be able to read this content: Get shareable link Sorry, a shareable link is not currently available for this article. Copy to clipboard Provided by the Springer Nature SharedIt

content-sharing initiative